722B7A0F-BF34-4368-8CFF-944FCBC7DAC4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.348226018396845
- age_years
- 45
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.485
- INTERFERON_GAMMA_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.446
- ALLOGRAFT_REJECTION+0.390
- APOPTOSIS+0.388
- IL6_JAK_STAT3_SIGNALING+0.375
- E2F_TARGETS+0.372
- G2M_CHECKPOINT+0.366
- TGF_BETA_SIGNALING+0.365
- INFLAMMATORY_RESPONSE+0.359
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.347
- KRAS_SIGNALING_DN-0.321
- HEDGEHOG_SIGNALING-0.274
- MYOGENESIS-0.185
- SPERMATOGENESIS-0.144
- APICAL_SURFACE-0.111
- APICAL_JUNCTION-0.053
- FATTY_ACID_METABOLISM-0.023
- WNT_BETA_CATENIN_SIGNALING-0.012
- ESTROGEN_RESPONSE_LATE+0.001
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934942 | — | — | 0.931 |
| 2 | SRR934802 | — | — | 0.930 |
| 3 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.926 |
| 4 | SRR934871 | — | — | 0.926 |
| 5 | 5C40F9B6-4A54-4861-9DE5-8852BF4B13E7 | — | — | 0.925 |
| 6 | B7B8F0C1-3C67-4582-AF82-A3DCD0398DEC | — | — | 0.925 |
| 7 | SRR934807 | — | — | 0.922 |
| 8 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.921 |
| 9 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.921 |
| 10 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.485 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.446 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| APOPTOSIS | 0.388 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.375 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.372 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.366 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.365 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.359 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.349 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.333 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.318 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.311 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.287 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.273 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.254 | Inavolisib | — uncovered |